Marvell Q2: Not Good Enough

Marvell reported Q2 revenue growth of 37% with minor beats, but growth is lagging AI chip leaders like Nvidia and Broadcom. Valuation remains expensive at ~60x forward adjusted earnings and ~180x GAAP, alongside material share dilution from ongoing equity issuances. Management guided to accelerating growth, targeting 50% revenue growth in Q3, but the gap versus peers suggests investors may stay cautious.

Analysis

MRVL looks like a classic “good business, bad stock” setup: the company is participating in AI spend, but the market is already pricing in a near-perfect catch-up path while quality-adjusted growth still trails the category leaders. At ~60x forward earnings, the multiple leaves little room for execution slippage, and ongoing dilution means per-share value creation is materially weaker than headline revenue growth suggests. In practice, that creates a ceiling on multiple expansion unless management proves it can translate AI design wins into sustained gross-margin and FCF conversion, not just top-line acceleration.

The competitive issue is second-order: capital appears to be concentrating in the few names that can credibly compound both growth and margins, which should continue to pull relative dollars away from MRVL into AVGO/NVDA. If the AI infrastructure tape stays strong, MRVL may still rally, but likely as a beta beneficiary rather than a leadership name; that means it is vulnerable to a rotation any time investors start demanding evidence of durable share gains versus simply “better than last quarter.” The key falsifier is a visible step-up in per-share EPS/FCF despite dilution over the next 1-2 quarters.

Near term, the risk is sentiment: another clean report can keep the stock elevated for days to weeks even if the long-run setup is mediocre. Over 1-3 months, the market will care less about revenue growth alone and more about whether guidance implies margin leverage and whether share count keeps expanding. Over 6-18 months, if AVGO and NVDA continue to outgrow MRVL, the relative multiple gap should widen rather than close.

Key Decisions for Investors

• Prefer long AVGO / short MRVL as a relative-value pair for the next 1-3 months: AVGO has the cleaner mix of AI scale, margin durability, and capital returns; MRVL needs multiple quarters of follow-through to justify its valuation.
• If initiating a directional short, use MRVL put spreads 6-10 weeks out rather than outright short stock; the name can stay expensive on AI enthusiasm, so structure the trade around a post-guidance reset or any sign of slowing sequential growth.
• Watch for a falsifier in the next earnings cycle: if MRVL shows share-count stabilization plus margin expansion and FCF per share inflects, cover shorts quickly; that would turn the setup from “story stock” to “earnings compounding.”
• For investors already long semis, rotate incremental exposure from MRVL into NVDA or AVGO on strength; the expected reward per unit of execution risk is better in the leaders than in the catch-up trade.